+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vasculitis Treatment Market by Treatment Type, Disease Type, Administration Route, End User, Distribution Channel - Global Forecast to 2030- Product Image
Vasculitis Treatment Market by Treatment Type, Disease Type, Administration Route, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Vasculitis Treatment Market by Treatment Type, Disease Type, Administration Route, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888985
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The vasculitis treatment market is being reshaped by innovation in biologics, evolving regulatory frameworks, and increasing precision in patient management. Senior decision-makers face new opportunities and operational challenges as segment trends, competitive shifts, and policy impacts drive strategic priorities across global healthcare environments.

Market Snapshot: Vasculitis Treatment Market Dynamics

The vasculitis treatment market grew from USD 202.92 million in 2024 to USD 213.64 million in 2025 and is projected to reach USD 275.68 million by 2030 at a CAGR of 5.23%. This growth is fueled by advances in immunology, precision medicines, and digital health integration. Treatment options have expanded to include targeted biologic therapies that address unmet clinical needs and offer improved safety compared to conventional protocols. Rapid adoption in established and emerging regions is shaping value-based procurement, and market participants face heightened demand for agile supply strategies and differentiated products across multiple healthcare delivery channels.

Scope & Segmentation

  • Treatment Type: Biologics (including Rituximab and Tumor Necrosis Factor Inhibitors such as Adalimumab, Etanercept, Infliximab), Corticosteroids, Immunosuppressants (Azathioprine, Cyclophosphamide, Methotrexate, Mycophenolate Mofetil), and Plasma Exchange.
  • Disease Type: ANCA Associated Vasculitis, Behcet Disease, Giant Cell Arteritis, IgA Vasculitis, and Takayasu Arteritis.
  • Administration Route: Intravenous, Oral, and Subcutaneous therapies.
  • End User: Ambulatory Care Centers, Clinics, Hospitals, and Specialty Centers.
  • Distribution Channel: Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Regional Coverage: Americas (including key US states and major markets in Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (markets such as the UK, Germany, France, Russia, Italy, Spain, United Arab Emirates, and others), and Asia-Pacific (notably China, India, Japan, Australia, South Korea, Southeast Asia, and more).
  • Leading Companies: Key market participants include F. Hoffmann-La Roche Ltd, ChemoCentryx, Inc., AbbVie Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Amgen Inc., UCB S.A., Novartis AG, Pfizer Inc., and Sanofi S.A.

Key Takeaways for Senior Decision-Makers

  • Therapeutic innovation is accelerating, with monoclonal antibodies and small molecules offering targeted options that improve remission and safety profiles.
  • Regulatory agencies have implemented faster review and adaptive approval mechanisms, streamlining the introduction of next-generation therapies.
  • Collaborative business models—linking biotechnology firms, contract research organizations, and academia—are enabling more efficient development pipelines.
  • Segmentation by disease subtype, administration route, and region reflects increasingly tailored approaches that drive both clinical outcomes and reimbursement strategies.
  • Supply chain resilience is becoming essential as market conditions and policy shifts, such as tariffs, challenge global operations and cost structures.
  • Ongoing digital transformation supports patient engagement and real-world evidence generation, influencing investment decisions and portfolio management.

Tariff Impact: How 2025 US Tariffs Reshape Supply Chains

The introduction of US import tariffs in 2025 has increased costs and volatility throughout the vasculitis treatment supply chain. Higher input and manufacturing expenses have pressured margins, leading market participants to diversify supplier networks and consider onshore production. Pricing dynamics have shifted as payers adopt value-based contracting to balance access and efficiency, incentivizing manufacturers to pursue cost-effective drug formulations and localized logistics.

Methodology & Data Sources

This report synthesizes rigorous secondary research from clinical trial databases, peer-reviewed journals, regulatory filings, and proprietary industry resources with in-depth primary interviews. Direct engagements with clinicians, payers, and pharma executives ensure qualitative insights are triangulated with quantitative data, maintaining methodological integrity and real-world relevance in market forecasting.

Why This Report Matters

  • Delivers actionable intelligence for portfolio prioritization and resource allocation in a market characterized by therapeutic innovation and policy flux.
  • Equips executives with strategic analysis on emerging technologies, supply chain adaptability, and potential regional growth pathways.
  • Supports robust investment and market access decisions, balancing stakeholder expectations amid evolving reimbursement and regulatory landscapes.

Conclusion

The vasculitis treatment market is evolving rapidly, defined by new therapies, regulatory adaptation, and shifting payer priorities. Decision-makers can capture growth by leveraging these trends, ensuring clinical benefits and sustainable market positioning across regions.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Vasculitis Treatment Market, by Treatment Type
8.1. Introduction
8.2. Biologics
8.2.1. Rituximab
8.2.2. Tumor Necrosis Factor Inhibitors
8.2.2.1. Adalimumab
8.2.2.2. Etanercept
8.2.2.3. Infliximab
8.3. Corticosteroids
8.4. Immunosuppressants
8.4.1. Azathioprine
8.4.2. Cyclophosphamide
8.4.3. Methotrexate
8.4.4. Mycophenolate Mofetil
8.5. Plasma Exchange
9. Vasculitis Treatment Market, by Disease Type
9.1. Introduction
9.2. ANCA Associated Vasculitis
9.3. Behcet Disease
9.4. Giant Cell Arteritis
9.5. IgA Vasculitis
9.6. Takayasu Arteritis
10. Vasculitis Treatment Market, by Administration Route
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Vasculitis Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Clinics
11.4. Hospitals
11.5. Specialty Centers
12. Vasculitis Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Vasculitis Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Vasculitis Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Vasculitis Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. ChemoCentryx, Inc.
16.3.3. AbbVie Inc.
16.3.4. Johnson & Johnson
16.3.5. Bristol-Myers Squibb Company
16.3.6. Amgen Inc.
16.3.7. UCB S.A.
16.3.8. Novartis AG
16.3.9. Pfizer Inc.
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. VASCULITIS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. VASCULITIS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. VASCULITIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. VASCULITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. VASCULITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. VASCULITIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ANCA ASSOCIATED VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BEHCET DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GIANT CELL ARTERITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IGA VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TAKAYASU ARTERITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. CANADA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 62. CANADA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. CANADA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 64. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 66. CANADA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 111. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 113. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 114. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 115. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 119. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 121. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. ITALY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. ITALY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 135. ITALY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. ITALY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 137. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 138. ITALY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 139. ITALY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 143. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 145. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 147. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 175. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 176. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 177. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 178. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 179. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. DENMARK VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. QATAR VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. QATAR VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 191. QATAR VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. QATAR VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 193. QATAR VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 194. QATAR VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 195. QATAR VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. QATAR VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 199. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 201. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 202. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 203. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. FINLAND VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 223. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 225. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 226. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 227. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. EGYPT VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 231. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 233. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 234. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 235. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. TURKEY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 247. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 249. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 250. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 251. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. NORWAY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. POLAND VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. POLAND VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 255. POLAND VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. POLAND VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 257. POLAND VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 258. POLAND VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 259. POLAND VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. POLAND VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. SWITZERLAND VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 278. CHINA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 279. CHINA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 280. CHINA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. CHINA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 282. CHINA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 283. CHINA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 284. CHINA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. CHINA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. INDIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 287. INDIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 288. INDIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 289. INDIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 290. INDIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 291. INDIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 292. INDIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. INDIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 295. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 296. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 297. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 298. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 299. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 300. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. JAPAN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. AUSTRALIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 316. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. SOUTH KOREA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 324. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. INDONESIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. THAILAND VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 327. THAILAND VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 328. THAILAND VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITO

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Vasculitis Treatment market report include:
  • F. Hoffmann-La Roche Ltd
  • ChemoCentryx, Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 213.64 Million
Forecasted Market Value ( USD ) by 2030 $ 275.68 Million
Compound Annual Growth Rate5.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Vasculitis Market - Product Image

Vasculitis Market

  • Report
  • 250 Pages
  • Global
From
Vasculitis Treatment - Global Strategic Business Report - Product Image

Vasculitis Treatment - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035 - Product Image

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
ANCA Vasculitis - Pipeline Insight, 2025 - Product Image

ANCA Vasculitis - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Vasculitis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035 - Product Image

Vasculitis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

  • Report
  • Global
From

About the Vasculitis Drug Market

Vasculitis is a group of diseases that cause inflammation of the blood vessels. It can affect any organ in the body, but is most commonly seen in the heart, lungs, and kidneys. Vasculitis drugs are used to treat the inflammation and reduce the risk of organ damage. These drugs are typically immunosuppressants, which work by suppressing the immune system and reducing inflammation. Common vasculitis drugs include corticosteroids, cyclophosphamide, and methotrexate. In addition to these drugs, there are also biologic agents, such as rituximab and tocilizumab, which are used to treat more severe cases of vasculitis. These drugs are designed to target specific parts of the immune system, and are often used in combination with other treatments. The vasculitis drug market is an important part of the cardiovascular drug market, as it provides treatments for a wide range of conditions. Companies in this market include Pfizer, Merck, AbbVie, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.